Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Tectonic Advisors LLC

Tectonic Advisors LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.4% during the fourth quarter, Holdings Channel reports. The fund owned 81,286 shares of the biopharmaceutical company’s stock after purchasing an additional 5,580 shares during the quarter. Tectonic Advisors LLC’s holdings in Gilead Sciences were worth $7,508,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. nVerses Capital LLC purchased a new stake in shares of Gilead Sciences during the third quarter worth about $25,000. HHM Wealth Advisors LLC raised its holdings in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 154 shares during the last quarter. Valued Wealth Advisors LLC lifted its stake in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares during the period. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $29,000. Finally, Crews Bank & Trust purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at $31,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

GILD opened at $97.99 on Wednesday. The stock has a market capitalization of $122.12 billion, a P/E ratio of 1,088.78, a price-to-earnings-growth ratio of 1.37 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The company’s 50 day simple moving average is $92.71 and its 200-day simple moving average is $86.32. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $99.45.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.29 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.34 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Piper Sandler raised their price target on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Wells Fargo & Company upped their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Cantor Fitzgerald restated a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a report on Wednesday, December 11th. Finally, Bank of America reissued a “buy” rating and set a $109.00 price target on shares of Gilead Sciences in a research report on Tuesday, December 10th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $98.39.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction on Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the sale, the chief financial officer now owns 138,919 shares of the company’s stock, valued at $12,886,126.44. This represents a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares of the company’s stock, valued at $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 572,824 shares of company stock worth $53,611,715 in the last quarter. Corporate insiders own 0.29% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.